Dr. Abdallah E. Kharnaf

Dr. Christopher S. King is a transplant pulmonologist and the Chief of Cardiovascular Critical Care at Inova Fairfax Hospital. He also serves as the Associate Medical Director of the Transplant and Advanced Lung Disease Program, Director of the Cardiovascular Intensive Care Unit at Inova Fairfax Hospital, the Pulmonary Fibrosis Foundation Center Director, and System Director of Respiratory Care Services for Inova. Dr. King is board certified in internal medicine, pulmonary medicine and critical care medicine. Dr. King serves as both a transplant pulmonologist and a medical intensivist for the medical critical care service at Inova Fairfax Hospital. He is also an Associate Clinical Professor of Medicine for the University of Virginia School of Medicine. Dr. King is a member of the medical honor society, Alpha Omega Alpha. While on active duty in the United States Army, he completed tours in Korea and Afghanistan as well as serving in Virginia and Texas. Dr. King has participated in clinical research throughout his training and during his tenure at Inova. His research interests are broad and include venous thromboembolism, interstitial lung disease and pulmonary hypertension. He has coauthored numerous publications including original research and review articles. He has lectured at national conferences and currently serves as a panel member for the American College of Chest Physicians' guidelines on antithrombotic disease. Dr. King is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Hypertension, Lung Transplant, and Endoscopy. Dr. King is currently accepting new patients.

Oksana A. Shlobin, MD, FCCP, serves as Medical Director for the Pulmonary Hypertension Program and Director of Outreach and Education for the Inova Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital. She is also an Associate Professor of Clinical Medicine at Georgetown University School of Medicine and an Associate Clinical Professor of Medicine at the University of Virginia. Dr. Shlobin is board certified in pulmonary and critical care medicine. Dr. Shlobin has been actively involved in clinical research both during her fellowship and her tenure at Inova. She is co-author of multiple publications, including original research manuscripts, abstracts and book chapters. Her research interests include pulmonary hypertension and interstitial lung diseases. Blog Posts What is Pulmonary Hypertension? Learn the Facts to Breathe Easy (November 2018) Pulmonary Hypertension is Serious. Learn to Spot the Signs (May 2017). Dr. Shlobin is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Pulmonary Hypertension, Acute Interstitial Pneumonia, Interstitial Lung Disease, Lung Transplant, and Endoscopy. Dr. Shlobin is currently accepting new patients.

Schar Chair, Advanced Lung Disease and Lung Transplant Medical Director, Advanced Lung Disease and Lung Transplant Program, Inova Schar Heart and Vascular Professor of Medical Education, University of Virginia, Inova CampusSteven D. Nathan, MD, FCCP, is the medical director of Inova’s Advanced Lung Disease Program and Lung Transplant Program. He is also a professor of medicine at the University of Virginia.Dr. Nathan is board certified in pulmonary diseases, critical care medicine and internal medicine. The author of more than 500 publications, Dr. Nathan is internationally recognized for his expertise in advanced lung diseases. He is co-editor of two books on idiopathic pulmonary fibrosis that provide pulmonologists and other healthcare workers with an up-to-date review of the background and advances in the field: Idiopathic Pulmonary Fibrosis and Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. He also has written original research manuscripts, abstracts, reviews and book chapters. Dr. Nathan is a reviewer for multiple journals and is on the editorial board for the journal, Thorax. He has served on multiple committees, including U.S. Food and Drug Administration advisory boards as well as steering committees for clinical trials in IPF and pulmonary hypertension, where he has also served as chair. Dr. Nathan is a member of several professional medical associations, including the American Thoracic Society, the American College of Chest Physicians, and the International Society for Heart and Lung Transplantation. He has delivered talks and been chairperson of numerous sessions at many national and international conferences. Dr. Nathan is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, Lung Transplant, and Prostatectomy. Dr. Nathan is currently accepting new patients.